{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:52:03Z","timestamp":1757620323609,"version":"3.44.0"},"reference-count":13,"publisher":"Termedia Sp. z.o.o.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pol J Radiol"],"abstract":"Purpose<\/jats:title>Hepatic fibrosis can be predicted using fibrosis-4 (FIB-4) and fibrosis-5 (FIB-5) scores. Functional liver imaging score (FLIS) provides valuable information regarding hepatic function. We aimed to assess whether easily obtained blood parameters (FIB-4 and FIB-5) may be used to discriminate preserved and impaired hepatic function based on FLIS.<\/jats:p><\/jats:sec>Material and methods<\/jats:title>Patients who underwent dynamic upper abdominal MRI with gadoxetic acid were retrospectively reviewed (<i>n<\/i> = 101, mean age 61.0 \u00b1 11.3 years). FLIS values were categorized as FLIS < 4 (impaired hepatic function) and FLIS \u2265 4 (preserved hepatic function). The discriminative potential of FIB-4 and FIB-5 was assessed by plotting ROC curves.<\/jats:p><\/jats:sec>Results<\/jats:title>While FIB-4 was significantly higher, FIB-5 was significantly lower in patients with FLIS < 4. They had significant discriminative value in distinguishing patients with preserved and impaired hepatic function (area under the ROC curves 0.794 for FIB-4 and 0.748 for FIB-5, <i>p<\/i>-values < 0.001). Comparison of the area under the 2 ROC curves revealed that FIB-4 and FIB-5 had similar discriminative values (<i>p<\/i> = 0.405). For FIB-4, a cut-off value of 4.2 had a sensitivity of 88.9%, specificity of 66.3%, PPV of 20.5%, and NPV of 98.4%, meaning that FIB-4 values of < 4.2 are valuable in ruling out FLIS < 4 (poor hepatic function). For FIB-5, a cut-off value of 36.2 had a sensitivity of 88.9%, specificity of 60.9%, PPV of 18.2%, and NPV of 98.2%, meaning that FIB-5 values of > 36.2 are valuable in ruling out FLIS < 4.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>FIB-4 and FIB-5 are valuable in discriminating preserved and impaired hepatic function based on FLIS scoring with similar diagnostic performance.<\/jats:p><\/jats:sec>","DOI":"10.5114\/pjr\/208327","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:08:32Z","timestamp":1757311712000},"page":"445-450","source":"Crossref","is-referenced-by-count":0,"title":["Fibrosis-4 and Fibrosis-5 scores in predicting functional liver imaging score"],"prefix":"10.5114","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8208-8613","authenticated-orcid":true,"given":"G\u00fcls\u00fcm","family":"K\u0131l\u0131\u00e7kap","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1950-3199","authenticated-orcid":false,"given":"Numan Ilteris","family":"\u00c7evik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3061","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"ref-1507051","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2013 2021 update. J Hepatol 2021; 75: 659-689.","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"ref-1507052","doi-asserted-by":"crossref","unstructured":"Attallah AM, Shiha GE, Omran MM, Zalata KR. A discriminant score based on four routine laboratory blood tests for accurate diagnosis of severe fibrosis and\/or liver cirrhosis in Egyptian patients with chronic hepatitis C. Hepatol Res 2006; 34: 163-169.","DOI":"10.1016\/j.hepres.2005.12.004"},{"key":"ref-1507053","doi-asserted-by":"crossref","unstructured":"Metwally K, Elsabaawy M, Abdel-Samiee M, Morad W, Ehsan N, Abdelsameea E. FIB-5 versus FIB-4 index for assessment of hepatic fibrosis in chronic hepatitis B affected patients. Clin Exp Hepatol 2020; 6: 335-338.","DOI":"10.5114\/ceh.2020.102157"},{"key":"ref-1507054","doi-asserted-by":"crossref","unstructured":"Shiha G, Seif S, Eldesoky A, Elbasiony M, Soliman R, Metwally A, et al. A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-significant and significant fibrosis in patients with chronic hepatitis C. Hepatol Int 2017; 11: 286-291.","DOI":"10.1007\/s12072-017-9796-z"},{"key":"ref-1507055","doi-asserted-by":"crossref","unstructured":"Ichikiwa S, Goshima S. Gadoxetic acid-enhanced liver MRI: everything you need to know. Invest Radiol 2024; 59: 53-68.","DOI":"10.1097\/RLI.0000000000000990"},{"key":"ref-1507056","doi-asserted-by":"crossref","unstructured":"Bastati N, Beer L, Mandorfer M, Poetter-Lang S, Tamandl D, Bican Y,et al. Does the functional liver imaging score derived from gadoxetic acid-enhanced MRI predict outcomes in chronic liver disease? Radiology 2020; 294: 98-107.","DOI":"10.1148\/radiol.2019190734"},{"key":"ref-1507057","doi-asserted-by":"crossref","unstructured":"Bastati N, Wibmer A, Tamandl D, Einspieler H, Hodge JC, Poetter-Lang S, et al. Assessment of orthotopic liver transplant graft survival on gadoxetic acid-enhanced magnetic resonance imaging using quali\u00adtative and quantitative parameters. Invest Radiol 2016; 51: 728-734.","DOI":"10.1097\/RLI.0000000000000286"},{"key":"ref-1507058","doi-asserted-by":"crossref","unstructured":"Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 2006; 43: 1317-1325.","DOI":"10.1002\/hep.21178"},{"key":"ref-1507059","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11010098"},{"key":"ref-1507060","doi-asserted-by":"crossref","unstructured":"Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology 2021; 161: 1657-1669.","DOI":"10.1053\/j.gastro.2021.07.049"},{"key":"ref-1507061","doi-asserted-by":"crossref","unstructured":"Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, et al. Consensus report from the 9(th) International. Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. Eur Radiol 2021; 31: 5615-5628.","DOI":"10.1007\/s00330-020-07637-4"},{"key":"ref-1507063","doi-asserted-by":"crossref","unstructured":"Poetter-Lang S, Bastati N, Messner A, Kristic A, Herold A, Hodge JC, et al. Quantification of liver function using gadoxetic acid-enhanced MRI. Abdom Radiol (NY) 2020; 45: 3532-3544.","DOI":"10.1007\/s00261-020-02779-x"},{"key":"ref-1507064","doi-asserted-by":"crossref","unstructured":"Beer L, Mandorfer M, Bastati N, Poetter-Lang S, Tamandl D, Sto\u00adyanova DP, et al. Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases. Eur Radiol 2019; 29: 6600-6610.","DOI":"10.1007\/s00330-019-06182-z"}],"container-title":["Polish Journal of Radiology"],"original-title":[],"link":[{"URL":"https:\/\/www.polradiol.com\/pdf-208327-128412","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.polradiol.com\/pdf-208327-128412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:08:36Z","timestamp":1757311716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.polradiol.com\/Fibrosis-4-and-Fibrosis-5-scores-in-predicting-functional-liver-imaging-score,208327,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":13,"alternative-id":["208327"],"URL":"https:\/\/doi.org\/10.5114\/pjr\/208327","relation":{},"ISSN":["1899-0967"],"issn-type":[{"type":"print","value":"1899-0967"}],"subject":[],"published":{"date-parts":[[2025,9,3]]}}}